Clinical Research Directory

Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel

Phase II, a randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts by combination of CO2 laser and Geniwa gel compared to laser CO2 combined with gel placebo. The clinical trial is conducted at National Dermatology Hospital, Hanoi, Vietnam.

Parent Education About Human Papillomavirus (HPV)

Human papillomavirus (HPV) vaccination is an effective strategy for preventing HPV-related diseases; however, parental knowledge and vaccination intention may influence vaccine uptake among children and adolescents. This randomized controlled trial evaluated the effect of a Health Belief Model (HBM)-based parent education intervention on HPV knowledge and HPV vaccination intention among parents of children aged 9-14 years. A total of 64 parents were enrolled and randomly assigned to an intervention group (n=32) or a control group (n=32). Following baseline assessment, the intervention group received a single, approximately 40-minute, face-to-face, nurse-led educational session based on the constructs of the Health Belief Model. The control group received no educational intervention during the five-week comparison period. HPV knowledge and vaccination intention were assessed at baseline and five weeks later. After completion of the five-week assessment, the control group received the same educational session for ethical reasons.

The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake

Type of Study: This study was planned to be an observational study. Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question\[s\] it aims to answer \[is/are\]: H1: There is a difference in the mean Human Papillomavirus (HPV) Knowledge Scale score between the intervention group women who participated in Human Papillomavirus (HPV) education and the control group women. H2: There is a difference between the intervention group women and the control group women in terms of their participation in HPV screening tests. H2: There is a difference between the intervention group women and the control group women in terms of their HPV vaccination status. Participants Participants will be assigned to a control and intervention group. Online training will be provided to the intervention group, and the results of the training will be reported.

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.

Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2

This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy.

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population. Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.